Immune Pharmaceuticals Inc

Immune Pharmaceuticals — EpiCept — Merger or Acquisition (February 2013)

30 slides from Immune Pharmaceuticals's merger presentation, Feb 22, 2013

  1. Slide 1: Immune EpiCept Merger Presentation

    IMMUNE EPICEPT MERGER PRESENTATION BIO CEO & INVESTOR CONFERENCE February 12, 2013 Improving Patient Lives Through Targeted Medicine

  2. Slide 2: Forward-Looking Statement

    Forward – Looking Statement This presentation contains forward looking statements that involve risks and uncertainties regarding the operations and future results of EpiCept. You should review the company's filings with the Securities and Exchange Commission, including without limitation the company

  3. Slide 3: Company Description

    Company Description The merger of Immune Pharmaceuticals, Ltd. and EpiCept Corporation will create a publicly-held pharmaceutical company focused on the development of novel pharmaceutical products for the treatment of inflammatory diseases and cancer. The Company will be an emerging leader in the d

  4. Slide 4: Highlights of Immune EpiCept Merger

    Highlights of Immune EpiCept Merger Merger agreement signed in November 2012. Closing targeted for the second quarter 2013. Company will have a portfolio of four products in development and a platform technology using antibody drug conjugates having significant advantages compared with those of othe

  5. Slide 5: Immune EpiCept Merger Details

    Immune EpiCept Merger Details EpiCept will be surviving legal entity upon closing, to be renamed Immune Pharmaceuticals, Inc. Company will continue as a US corporation. Shareholder split approximately 20% EpiCept/ 80% Immune upon closing, subject to certain adjustments. EpiCept shareholder approval

  6. Slide 6: Board of Directors

    Board of Directors Herve de Kergrohen,MD,MBA Board Director UBS, Bellevue, Lombard Isaac Kobrin, MD Board Director, Roche, Actelion Daniel Teper, PharmD, MBA Chairman Novartis, GSK, Sanofi, Bionest David Sidransky, MD, PhD Vice Chairman Imclone, Rosetta, Johns Hopkins Pierre Albouy Board Director Ba

  7. Slide 7: Immune - EpiCept Priority Development

    Immune - EpiCept Priority development of bertilimumab, Phase II multiple indications GI- Crohn’s Disease & ulcerative colitis Respiratory - severe asthma Dermatology NanomAbs – second generation antibody drug conjugate oncology pipeline Lead candidate gemcitabine paclitaxel anti-ferritin nanomAbs fo

  8. Slide 8: Immune/EpiCept Pipeline

    Immune/EpiCept Pipeline Large, diversified pipeline addressing unmet needs in important patient populations *Medimmune AZ License to iCo Therapeutics with option for Immune; **Property of EpiCept

  9. Slide 9: Bertilimumab Neutralizes Eotaxin-1: Multiple Potential Indications

    Gastro-Enterology Ulcerative Colitis Crohn’s Disease Respiratory Severe Asthma Chronic obstructive pulmonary disease (COPD) Ophthalmology Verneal Keratoconjunctivitis (VKC) Atopic Keratoconjunctivitis (AKC) Age Related Macular Degeneration (AMD) Dermatology Bullous Pemphigoid Atopic Dermatitis Oncol

  10. Slide 10: Eotaxin-1 Regulates Eosinophilic Inflammation

    Eotaxin-1 Regulates Eosinophilic Inflammation in Crohn’s Disease, Ulcerative Colitis and Severe Asthma 10 1996 Nature Publishing Group http://www.nature.com/nature medicine ARTICLES Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosino

  11. Slide 11: Bertilimumab Clinical Experience Supports Further Development

    Bertilimumab Clinical Experience Supports Further Development Phase I/ IIa in healthy volunteers (#20) and allergic patients ( # 100) Safe and well tolerated in single dose IV, nasal and ocular administration Dose dependent pharmacological activity on eosinophils Close to 100% effect on eosinophils

  12. Slide 12: Eotaxin-Induced Eosinophil Shape Change Inhibition

    Eotaxin-Induced Eosinophil Shape Change Close to 100% Inhibition- Prolonged Effect 12 Figure 6: Percent Inhibition of Eotaxin Induced Eosinphil Shape Change, Compared with Baseline, Following Administration of 1,5 and 10 mg/kg of Bertilimumab Inhibition of Baseline (pre-dose) Eotaxin Induced Eosinop

  13. Slide 13: Crohn's Disease and Ulcerative Colitis Proof of Concept

    Crohn’s Disease and Ulcerative Colitis Proof of Concept Phase II in High Tissue Eotaxin-1 UC Initiated Current therapy in non-responders to first line are anti-TNF mAbs (Humira, Remicade) Significant unmet medical need with lack of sustained response and risk of severe adverse events Eotaxin-1 bioma

  14. Slide 14: Targeting Eotaxin-1 with Bertilimumab

    Targeting Eotaxin-1 with Bertilimumab Rationale for Phase II in Ulcerative Colitis Supported by Experimental and Clinical Data 14 K.Wilson DDW 2013 Increased Tissue Eotaxin-1 (CCL11) in UC in Correlation with Severity of Disease Eosinophil associated genes in the inflammatory bowel disease 4 region:

  15. Slide 15: Bertilimumab Target Profile in UC & CD

    Bertilimumab can reduce signs and symptoms and induce remission in patients with moderately to severely active UC or CD who have High EOTAXIN TISSUE LEVELS Bertilimumab Target Profile in UC & CD 15

  16. Slide 16: Bertilimumab Phase II Ulcerative Colitis Trial

    Bertilimumab Phase II Ulcerative Colitis Proof of Concept Trial Double blind placebo controlled trial in 69 patients 46 on bertilimumab 7mg/ kg; 23 on placebo Drug administration at week 0, 2 and 4 6 week end point is clinical response (UC Mayo Clinic Index); follow up until week 12 Study expected t

  17. Slide 17: When Asthma Cannot be Controlled

    When Asthma Cannot be Controlled Bertilimumab Targets Severe Asthma Patients with Eosinophilic Inflammation 10% most severe patients not controlled by corticosteroids and bronchodilators- moderate unstable and severe asthma High burden of asthma exacerbations and related hospitalization Clinical res

  18. Slide 18: Bertilimumab Rationale in Severe Asthma

    Bertilimumab Rationale in Severe Asthma Eotaxin-1 levels correlates with asthma disease severity Bertilimumab reduces chemotaxis of eosiniphils induced by sputum from moderate unstable and severe asthma patients 18 Figure 11: The effect of iCo-008 (CAT-213; 100nM) and CAT-001 (100nM, null control) o

  19. Slide 19: Omalizumab Down-Regulation of Eotaxin-1

    Omalizumab (Xolair®) Down-Regulation of Eotaxin-1 May Explain Anti-Inflammatory and Clinical Benefits 19 Zietkowski & all, Advances in Medical Sciences, 2011 Figure 1. Concentrations of eotaxin in EBC before the treatment, and subsequent changes which were observed after 16 weeks in both groups of a

  20. Slide 20: Targeting Eotaxin and/or IL-5 in Severe Asthma

    Targeting Eotaxin 1 and/or IL-5 in Severe Asthma Anti-IL-5 mAbs mepoluzimab (GSK) and resiluzimab (Teva) Phase II/III results in moderate unstable and severe eosinophilic asthma have demonstrated effect on most relevant FEV1 and asthma exacerbation clinical end points. Potential complementary/ syner

  21. Slide 21: Targeting Eotaxin-1 in Bullous Pemphigoid

    Targeting Eotaxin-1 ( CCL11) in Bullous Pemphigoid A Dermatological Orphan Disease Up-regulation of CCL11 is associated with activated eosinophils in BP IL-5 and CCL11 both involved in regulation of eosinophils in BP Mepoluzimab ( GSK) initiated Phase II trial in BP in 2012 Bertilimumab Phase II in

  22. Slide 22: NanomAbs Next Generation Antibody Drug Conjugates

    NanomAbs Next Generation Antibody Drug Conjugates Exclusive worldwide license from Hebrew University of Jerusalem Potential advantages over SGEN/IMGN technology include higher payload and drug versatility Similar technologies ( Bind Biosciences, Merrimack) validated approach in Phase I clinical tria

  23. Slide 23: NanomAbs' Advantage: mAb Driven Endocytosis

    NanomAbs’ Advantage: mAb Driven Endocytosis Maximized Chemotherapy Drug Accumulation into Tumor Cells NanomAbs preferential uptake into tumor tissue based on the enhanced permeability and retention effect A B C Active targeting to the receptor by mAb conjugated to the NanomAb mAb Induces highly effi

  24. Slide 24: AmiKet Topical Cream

    AmiKet™ Topical cream for the relief of pain associated with well known neuropathies, CIPN, PHN, DPN Twice daily application of 4% amitriptyline plus 2% ketamine combination provides pain relief equivalent to current therapies Over 1,700 patients treated in nine Phase I/II clinical trials, including

  25. Slide 25: Crolibulin

    Crolibulin TNFR Survival Factors RB Cyclin D/ CDK2,4,5 Bcl-xl Cyclin E/CDK2 Cyclin A/CDK2 Cyclin A/B/ CDK2 FasL IkB RTKs Ras Raf MEKK JNK/SAPK Fos/Jun Heterodimers TRAF IKK1/ IKK2 inactive complex Calcineurin PI3K Akt Bad Smac/Diablo IAP/Hsp70 GSK-3 Flip Bcl-2 Apoptosis Mitochondria Apoptosome M G1

  26. Slide 26: Azixa

    Azixa® Small molecule, apoptosis inducer with VDA activity, Crosses blood brain barrier and concentrates 15x in the central nervous system compared with blood levels. Regained from Myrexis in August 2012 upon termination of license agreement. Clinical data and other technology licensed from Myrexis

  27. Slide 27: Ceplene

    Ceplene® Ceplene® in combination with IL-2 is first and only therapeutic regimen shown to prevent relapse and prolong LFS in AML patients in remission EU approval in 2008; licensed to Meda SA; European rights sold to Meda in 2012 to substantially reduce operating expenses in face of slow sales ramp

  28. Slide 28: Financial Status

    Financial Status Proxy statement is expected to be filed with Securities and Exchange Commission within next several weeks. Based on time required to obtain SEC clearance, EpiCept shareholder meeting to approve actions related to the merger is expected to be held during the second quarter of 2013. M

  29. Slide 29: Immune EpiCept Merger

    Immune EpiCept Merger Merger with Immune provides EpiCept shareholders with opportunity to realize value from current pipeline and to participate in the significant opportunity of the Immune pipeline. Phase II/ III clinical stage portfolio with focus on antibody therapeutics Multiple value creating

  30. Slide 30: Contact Information

    Contact information www.immunepharmaceuticals.com Dr. Daniel Teper, CEO, IMMUNE Pharmaceuticals Daniel.teper@immunepharmaceuticals.com Robert Cook, CEO, EpiCept Corporation rcook@epicept.com 30

EpiCept — Merger or Acquisition (February 2013) on 6ix